Clinical Perspectives for Positioning IL-17 Inhibitors in Psoriasis Care

In this episode, the panelists share clinical perspectives on positioning IL-17 inhibitors within psoriasis treatment. The experts discuss that among available biologic options, IL-17 inhibitors provide rapid and durable skin clearance, making them an important choice for patients with moderate to severe psoriasis. They highlight the significance of dual IL-17A and IL-17F inhibition, noting that it offers greater depth of response compared to targeting IL-17A alone. When selecting therapy, the panel emphasizes tailoring treatment to individual patient factors—such as nail involvement, disease burden, or potential psoriatic arthritis risk. They also consider head-to-head data showing that IL-17 inhibitors can achieve superior outcomes compared with other classes, including IL-23 inhibitors, in certain patient groups. The experts conclude that positioning IL-17 inhibitors early in the treatment algorithm may not only improve skin outcomes but also support prevention of disease progression.